Zoledronic Acid Treatment of Spontaneous Osteonecrosis of the Knee

• Status: Withdrawn
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and efficacy of zoledronic acid in patients presenting with spontaneous osteonecrosis of the knee.

• Phase: Phase 2

Details

• Lead Sponsor: Novartis
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• Adults 40-85 years of age

• Diagnosis of painful osteonecrosis of the knee within the last month.

Exclusion Criteria:

• Intravenous (iv) bisphosphonates within the last 2 years.

• Abnormal thyroid, kidney or liver function.

• Abnormal blood calcium or alkaline phosphatase levels.

Other protocol-defined inclusion/exclusion criteria may apply